Cover Image

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease

Saved in:

Bibliographic Details
Main Authors:	Li-Min Zhao (Author), Ze-Lin Zhan (Author), Jie Ning (Author), Mei Qiu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Unlocking the potential: boosting SGLT2 inhibitor uptake to prevent the cardiorenal consequences of chronic kidney disease
by: Julio A. Lamprea-Montealegre
Published: (2024)

Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease
by: Yaning Zheng, et al.
Published: (2022)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022)

Administration of finerenone in chronic kidney disease
by: Mohsen Akhavan Sepahi, et al.
Published: (2023)

Research advances on renoprotective mechanism of SGLT-2 inhibitors in non-diabetic kidney disease
by: Feng Liu, et al.
Published: (2023)

Comparative Efficacy of Finerenone versus Canagliflozin in Patients with Chronic Kidney Disease and Type 2 Diabetes: A Matching-Adjusted Indirect Comparison
by: David Cherney, et al.
Published: (2024)

SGLT-2 Inhibitors in Kidney Transplant Recipients: Our Story So Far
by: Luís Leite de Sousa, et al.
Published: (2023)

Relative efficacy of five SGLT2 inhibitors: a network meta-analysis of 20 cardiovascular and respiratory outcomes
by: LiGang Huang, et al.
Published: (2024)

Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
by: Marcin Czarkowski, et al.
Published: (2022)

Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease
by: Nejc Piko, et al.
Published: (2024)

FINERENONE IN CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: A FIDELITY ANALYSIS OF LEFT VENTRICULAR HYPERTROPHY
by: Luis Matavelli, et al.
Published: (2023)

Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes: The FIDELIO-DKD Subgroup from China
by: Haitao Zhang, et al.
Published: (2023)

The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
by: Sahar H. Elhini, et al.
Published: (2022)

SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice
by: Nerea Martos-Guillami, et al.
Published: (2024)

The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury
by: Chang Chu, et al.
Published: (2019)

SGLT2 Inhibitors in the Treatment of Diabetic Kidney Disease: More than Just Glucose Regulation
by: Jasna Klen, et al.
Published: (2023)

Association Between SGLT2is and Cardiovascular and Respiratory Diseases: A Meta-Analysis of Large Trials
by: Dao-Gen Yin, et al.
Published: (2021)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023)

Efficacy and Safety of Finerenone in Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
by: Ming-Zhu Zhang, et al.
Published: (2022)

Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials
by: Shiwen Yang, et al.
Published: (2023)

The use of SGLT2 inhibitors in the treatment of cognitive disorders
by: Marta Lato, et al.
Published: (2023)

SGLT-2 inhibitors: Post infarction interventional effects
by: Pugazhenthan Thangaraju, et al.
Published: (2023)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018)

SGLT2 inhibitors: suggestions from the amphibian world
by: Stefano Michelassi
Published: (2022)

SGLT2 Inhibitors and Fracture Risk in Elderly Population
by: Vishal R Tandon, et al.
Published: (2023)

Role of Finerenone in the Treatment of Diabetic Kidney Disease: Patient Selection and Clinical Perspectives
by: Shaikh A, et al.
Published: (2022)

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes
by: Nauck MA
Published: (2014)

Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review
by: Marina V. Leonova
Published: (2024)

Tumor risks of finerenone in patients with type 2 diabetes mellitus complicated with chronic kidney disease: a meta-analysis and systematic review of randomized controlled trials
by: Yue Du, et al.
Published: (2024)

SGLT2-Inhibitors - significant role in Heart Failure treatment
by: Karol Wielgus, et al.
Published: (2024)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
by: Kai-Fan Tsai, et al.
Published: (2021)

Reply to SGLT-2 inhibitors: Post-infarction interventional effects
by: Pasquale Paolisso, et al.
Published: (2023)

SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
by: Maria Elena Lunati, et al.
Published: (2022)

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
by: Runfang Pan, et al.
Published: (2024)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)

SGLT2 inhibitors for treatment of Type 2 diabetes mellitus: Focus on Canagliflozin
by: Santosh Kumar Singh, et al.
Published: (2014)

SGLT2 Inhibitors Decrease Overhydration and Proteasuria in Patients with Chronic Kidney Disease: A Longitudinal Observational Study
by: Anja Schork, et al.
Published: (2024)

Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
by: Chun Xing Li, et al.
Published: (2023)